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Abstract 
Cardiovascular diseases have become an increasing clinical issue worldwide. Acute ischaemic in-
jury and chronic cardiomyopathies lead to permanent loss of cardiac tissue and ultimately heart 
failure. Current therapies widely aim to attenuate the pathological changes that occur after in-
jury and to reduce risk factors of cardiovascular diseases. However, they do not improve the pa-
tient’s quality of life or the prognosis more than moderate. A new challenge in the treatment of 
the cardiovascular disease is cellular transplantation or cellular cardiomyoplasty. Different types 
of stem cells have been used for stem cell therapy. Clinical trials using primary bone-marrow-
derived cells and skeletal myoblasts have also shown some encouraging results. An additional 
clinical and pre-clinical study to further enhance the beneficial effects of cell therapy is neces-
sary. Recent studies have shown that there are various pools of putative resident stem cells in an 
adult heart, raising the hope that these cells can contribute to the treatment of cardiovascular 
diseases. 
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Introduction 
Cardiovascular disease is one of the major causes of 
death  worldwide  accounting  for  nearly  17  million 
deaths per annum according to the World Health Or-
ganization  Atherosclerosis  is  a  complex  trait  which 
arises from the interaction of a number of genetic and 
environmental  factors  and  complex  gene-
environment interactions.1 
  Atherosclerosis involves multiple vascular territo-
ries such as carotids, coronaries and peripheral ves-
sels. The molecular mechanisms leading to atheroscle-
rosis are still unclear.1 Many epidemiological studies 
indicated that hypertension, diabetes, obesity, smok-
ing and hyperlipidaemia are risk factors contributing 
to coronary artery diseases (CAD).2-4 For those suffer-
ing  from  cardiovascular  diseases,  stem  cell  biology 
represents  a  new  medical  frontier.  Researchers  are 
working towards using stem cells to replace damaged 
heart  cells  and  restore  cardiac  function.  Although 
there  is  much  excitement  because  researchers  now
know that adult and embryonic stem cells can repair 
damaged heart tissue, many questions remained to be 
answered  before  clinical  applications  can  be  made. 
Unlike other organs such as liver, heart lacks adequate 
auto-regeneration ability.5 There are several therapies 
for heart failure including medical, surgical and stem 
cell or progenitor cell therapy. Cell therapy has be-
come  a  new  potential  cardiovascular  therapeutical 
tool recently.6 The effective goals of cell therapy are 
myocardial regeneration and neovascularisation. Sev-
eral different types of stem cells have been studied to 
find the best source for cardiac regeneration (figure 1). 
 
Stem cell populations for cardiovascular disease 
Embryonic stem cells (ESCs) 
Embryonic stem cells in mouse and human can be 
extracted from the inner body of the blastocyst and 
can be cultured in vitro.7,8 From the various stem cell 
populations  studied  so  far,  the  ESC  cells  have  the 
greatest  capacity  for  cardiac  cell  differentiation  and 
long-term survival.9 However, no clinical trial in hu-
man for myocardial repair has been applied yet. 
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Figure 1. Stem cell therapy for cardiovascular disease. (Figure design By Arlen Mokhtarzadeh) 
 
Skeletal myoblasts  
Skeletal myoblasts which are called satellite cells or 
skeletal muscle precursors are present in skeletal mus-
cles.  These  cells  are  further  differentiated  than  the 
ESCs. After two or three weeks of cell culture, they 
can be implanted.10 Skeletal myoblasts have the capac-
ity  to  differentiate  in  vitro  into  non-muscle  cell 
types.11,12 Finally, there are several barriers that still 
remain including variability and complexity in the ap-
plication of skeletal myoblast populations.13 
 
Bone-marrow-derived stem cells 
Bone marrow mononuclear cell can be derived from 
bone  marrow  and  peripheral  blood.  Easy  isolation, 
safety  and  feasibility  for  their  implantation  are  the 
advantages to consider, although, investigations found 
limited or no differentiation of bone marrow cells to 
cardiovascular  cell  types.14,15  Endothelial  progenitor 
cells (EPCs) is another bone marrow cell type which 
is important in neovasculogenesis. 
 
Mesenchymal stem cells (MSCs) 
Mesenchymal  stem  cells  derive  from  bone  marrow 
and  adipose tissue.  It  is  easy  to  isolate  and  culture 
these cells in vitro. The MSCs are multipotent and 
they are less-immunogenic than others.16 A problem 
with mesenchymal stem cell engraftment was forma-
tion of bone and cartilage in heart after transplanta-
tion. The microenvironment at the region of engraft-
ment of stem cells is very important and it may cause 
differentiation of stem cells into unwanted cell types 
 
Important parameters in cell therapy 
In order to consider cell therapy as clinically relevant, 
many parameters need to be optimized including cell 
type, cell function, cell number and route of adminis-
tration. As mentioned earlier about different cell types 
for cell therapy, in all controlled studies, significant 
positive  results  have  been  observed  in  multipotent 
cells which were transplanted.17-19 The cell numbers 
used in cell therapy for chronic coronary artery dis-
ease can be between 3.106 to 800.106 cells. There is no 
certain correlation between the number of cells admi-
nistered and its effect on heart failure. Another para-
meter  that  is  associated  with  cell  therapy  improve-
ment is the cell functionality.20,21 Route of administra-
tion which considered in surveys is not a determining 
factor  for  successive  delivery,  although  there  is  no 
direct comparison between routs of administration in 
cell therapy for cardiovascular diseases. 
 
Mechanism of Cell Therapy 
These different stem cell types have different poten-
tial mechanisms of action. One of the proposed me-
chanisms is myogenesis which is more controversial 
than the other mechanism, particularly in transdiffe-SOME NOTES ON STEM CELL THERAPY IN CARDIOVASCULAR DISEASES  
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rentiation  of  bone  marrow  derived  cells  into  heart 
cells. It is not yet clear if transplanted cells themselves 
differentiate or paracrine effects of the transplanted 
cells  stimulate  stem  cells  differentiation  or  both  of 
these factors act. The other proposed mechanism of 
cell therapy is angiogenesis. Bone marrow cells may 
be able to secret multiple angiogenic substances and 
these  cells  can  be  differentiated  into  cells  with  the 
ability to create new blood vessels. Strategies to aug-
ment  cell  function,  survival,  and  homing  could  be 
crucial  to  improve  success  rates  for  cell  therapy. 
There are two strategies which may improve the effi-
ciency of cell therapy: 1) pretreatment of the cells ex 
vivo by small molecules or modification of the cells by 
genes to improve the function, survival, and homing 
capacity after infusion or injection; and 2) activation 
of  the  target  tissue  to  specifically  augment  signals 
capable of attracting infused cells or modulating cell 
function and survival.22 Researchers studying the use 
of embryonic stem cells are also trying to determine 
why, in animals, most implanted stem cells re-enter 
the circulation or die rather than engraft to the heart 
muscle wall to form new muscle cells. They are also 
searching for the ways to use gene therapy to increase 
the number of embryonic stem cells that live on as 
new muscle cells. 
 
Stem cell research in Iran 
In the Middle East, the highest absolute number of 
patients  with  cardiovascular  disease  is  estimated  in 
Iran.  While  combating  major  risk  factors  including 
hypertension, smoking, and hyperlipidemia, is crucial 
for improving health of the nation, control programs 
regarding  CAD,  via  modifying  the  modifiable  risk 
factors  are  envisaged.23  Several  stem  cell  therapies 
have been performed in Iran. In a survey in Iran the 
efficacy of autologous bone marrow derived mesen-
chymal stem cells in improving heart function in pa-
tients  with  old  myocardial  infarction  was  investi-
gated.24 In another study in Iran by Ghavamzadeh et 
al, hematopoietic stem cell therapy was reported to be 
a choice treatment of many malignant, non-malignant, 
and  genetic  diseases.  They  introduced  105  cellular 
therapies  for  post-myocardial  infarction,  multiple 
sclerosis, cirrhosis, head of femur necrosis, and renal 
cell  carcinoma.  About  30  patients  were  re-
transplanted  and  about  74.9%  of  the  patients  re-
mained alive between one to 168 months after stem 
cell  transplantation.  Nearly  25.1%  of  their  patients 
died  after  stem  cell  transplantation.  The  causes  of 
deaths were relapse, infections, hemorrhagic cystitis, 
graft versus host disease, and others.25 
Discussion  
Several phenotypically distinct cell populations have 
been utilized for heart failure. In summary, pluripo-
tent  (e.g.,  mesenchymal  stem  cells),  totipotent  
(e.g., embryonic) and multipotent (e.g., tissue specific) 
stem  cells  can  be  applied.26  Multipotent  stem  cells 
have less ability to differentiate than embryonic stem 
cells, but embryonic stem cells are able to differentiate 
into cardiomyocytes.27,28 In several studies, it has been 
shown that several pluripotent stem cells are able to 
differentiate into cardiomyocytes and lead to neovas-
cularisation such as haematopoietic, mesenchymal and 
endothelial progenitor stem cells.29-32 Many research-
ers now believe that cellular therapy will likely revolu-
tionize approaches to heart failure. 
 
Future perspectives  
Finally,  proper  cell  type,  cell  number  and  route  of 
administration still need to be determined and genera-
tion of unwanted cell types must be prevented. Re-
searchers  have  to  determine  exactly  how  the  stem 
cells  work.  The  main  challenge  for  developing  any 
stem cell based therapy for heart diseases is the con-
trol of cell migration, proliferation and differentiation 
ex vivo as well as in vivo. The initial trials with pa-
tients will be phase I studies. However, the validity 
for the future of stem cell therapy depends on the 
benefits obtained in the human phase II and III clini-
cal trials. Stem cell therapy for heart failure needs fur-
ther investigation and much more work needs to be 
done. Stem cell therapies in conjunction with current 
treatments  may  help  improve  the  quality  of  life  in 
cardiovascular disease patients. 
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